Celyad plans to delist from Nasdaq amid cash woes

New York during the COVID-19 emergency.

Massimo Giachetti

Celyad Oncology (NASDAQ:CYAD) is delisting its American Depositary Shares (ADSs) from Nasdaq.

The company’s board approved the voluntary delisting of the ADSs, representing ordinary shares, termination of its American Depositary Receipt (ADR) facility and deregistration with the U.S. Securities and Exchange Commission (SEC).


Business Asia
the authorBusiness Asia

Leave a Reply